Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosis.
Chang YT, Kearns PKA, Carson A, Gillespie DC, Meijboom R, Kampaite A, Valdés Hernández MDC, Weaver C, Stenson A, MacDougall N, O'Riordan J, Macleod MA, Carod-Artal FJ, Connick P, Waldman AD, Chandran S, Foley P. Chang YT, et al. Among authors: kearns pka. Mult Scler Relat Disord. 2023 Jan;69:104429. doi: 10.1016/j.msard.2022.104429. Epub 2022 Nov 24. Mult Scler Relat Disord. 2023. PMID: 36493562 Free article.
Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register.
Kearns PKA, Paton M, O'Neill M, Waters C, Colville S, McDonald J, Young IJB, Pugh D, O'Riordan J, Weller B, MacDougall N, Clemens T, Dibben C, Wilson JF, Castro MC, Ascherio A, Chandran S, Connick P. Kearns PKA, et al. J Neurol. 2019 Oct;266(10):2376-2386. doi: 10.1007/s00415-019-09413-x. Epub 2019 Jun 11. J Neurol. 2019. PMID: 31187189 Free PMC article.
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis.
Kearns PKA, Martin SJ, Chang J, Meijboom R, York EN, Chen Y, Weaver C, Stenson A, Hafezi K, Thomson S, Freyer E, Murphy L, Harroud A, Foley P, Hunt D, McLeod M, O'Riordan J, Carod-Artal FJ, MacDougall NJJ, Baranzini SE, Waldman AD, Connick P, Chandran S. Kearns PKA, et al. BMJ Open. 2022 Jun 29;12(6):e058506. doi: 10.1136/bmjopen-2021-058506. BMJ Open. 2022. PMID: 35768080 Free PMC article.
Longitudinal retinal imaging study of newly diagnosed relapsing-remitting multiple sclerosis in Scottish population: baseline and 12 months follow-up profile of FutureMS retinal imaging cohort.
Chen Y, Larraz J, Wong M, Kearns P, Brown F, Martin SJ, Connick P, MacDougall N, Weaver C, Dhillon B, Chandran S. Chen Y, et al. BMJ Open Ophthalmol. 2022 Jul;7(1):e001024. doi: 10.1136/bmjophth-2022-001024. BMJ Open Ophthalmol. 2022. PMID: 36161838 Free PMC article.
Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland.
Meijboom R, Wiseman SJ, York EN, Bastin ME, Valdés Hernández MDC, Thrippleton MJ, Mollison D, White N, Kampaite A, Ng Kee Kwong K, Rodriguez Gonzalez D, Job D, Weaver C, Kearns PKA, Connick P, Chandran S, Waldman AD. Meijboom R, et al. Among authors: kearns pka. Wellcome Open Res. 2022 Mar 16;7:94. doi: 10.12688/wellcomeopenres.17731.1. eCollection 2022. Wellcome Open Res. 2022. PMID: 36865371 Free PMC article.
Quantitative T1 brain mapping in early relapsing-remitting multiple sclerosis: longitudinal changes, lesion heterogeneity and disability.
Harper JG, York EN, Meijboom R, Kampaite A, Thrippleton MJ, Kearns PKA, Valdés Hernández MDC, Chandran S, Waldman AD; FutureMS consortium. Harper JG, et al. Among authors: kearns pka. Eur Radiol. 2024 Jun;34(6):3826-3839. doi: 10.1007/s00330-023-10351-6. Epub 2023 Nov 9. Eur Radiol. 2024. PMID: 37943312 Free PMC article.
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.
Pal S, Chataway J, Swingler R, Macleod MR, Carragher NO, Hardingham G, Selvaraj BT, Smith C, Wong C, Newton J, Lyle D, Stenson A, Dakin RS, Ihenacho A, Colville S, Mehta AR, Stallard N, Carpenter JR, Parker RA, Keerie C, Weir CJ, Virgo B, Morris S, Waters N, Gray B, MacDonald D, MacDonald E, Parmar MKB, Chandran S; MND SMART Investigators. Pal S, et al. Lancet Neurol. 2024 Nov;23(11):1097-1107. doi: 10.1016/S1474-4422(24)00326-0. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307154 Free article. Clinical Trial.
20 results